Memory Pharmaceuticals Corp &
Roche Holding AG | Update Date: 01/02/09 |
| Date Announced: 11/25/08 |
| Value (million $USD): 50.2 million U.S. Dollar |
|
| Status: Part Comp | |
| TRANSACTION DETAILS |
|---|
| Date Announced | 11/25/08 | | |
| Date Originally Announced | 11/25/08 | | |
| Format | Merger | Acquisition techniques | Tender Offer; Tender/Merger |
| Attitude | Friendly | Agency | Unspecified Regulatory Auth. |
| Value | 50.2 million U.S. Dollar | Advisor Fees | n/a |
| SYNOPSIS |
|---|
| US - Roche Holding AG completed its tender offer to acquire all the outstanding common stock of Memory Pharmaceuticals Corp (MP), a biopharmaceutical company, for $0.61 in cash per share, or a total value of $50.168 mil, by accepting 7.1369 mil shares, or 88.96% of MPs common shares outstanding. The offer was conditioned upon at least a majority of MP's shares being tendered. The transaction had been subject to customary closing conditions. |
| TARGET |
|---|
| Name | Memory Pharmaceuticals Corp (MEMY) |
| Industries | Commercial physical and biological research; Noncommercial research organizations; Medical laboratories; Pharmaceutical preparations; Medicinal chemicals and botanical products |
| City | Montvale |
| State | NJ |
| Nation | United States |
| Incorporated in | n/a |
| Public Status | Public |
| Business Description | Memory Pharmaceuticals Corp is a biopharmaceutical company, headquartered in Montvale, New Jersey. The company is focused on developing innovative drugs for the treatment of debilitating central nervous system (CNS) disorders. The company was founded in 1998. |
| Advisors | Lazard |
| Target Sales | 7.1 million U.S. Dollar |
|
| ACQUIROR |
|---|
| Name | Roche Holding AG (Zurich : ROG) |
| Industries | Biological products, except diagnostic substances; Medicinal chemicals and botanical products; In vitro and in vivo diagnostic substances; Industrial organic chemicals, nec; Chemicals and chemical preparations, nec; Surgical and medical instruments and apparatus; Commercial physical and biological research; Offices of holding companies, nec |
| City | Basel |
| State | n/a |
| Nation | Switzerland |
| Incorporated in | n/a |
| Public Status | Public |
| Business Description | Roche Holding AG, headquartered in Basel, Switzerland, manufactures pharmaceuticals, medicines, diagnostics, chemicals, diagnostic kits, and medical instruments. The Group's principal activities are to discover, develop, manufacture and market novel health care solutions. The Group operates through two segments namely Pharmaceuticals and Diagnostics. The Pharmaceuticals division includes prescription and manufacturing of pharmaceutical products. The Pharmaceutical segment has three sub-divisions namely Roche Prescription, Genentech Prescription and Chugai Prescription. Diagnostic segment provides products and services in all fields of medical testing. It also provides reagents and test kits for molecular and cell biology, analytical systems and reagents for clinical chemistry, immunochemistry, hematology and coagulation. Diagnostics division consists of five business areas: Diabetes Care, Near Patient Testing, Centralized Diagnostics, Molecular Diagnostics and Applied Science. It operates in Switzerland, European Union, United States, North America, Latin America, Japan, Asia, Africa, Australia and Oceania. The company was founded in 1896. |
| Advisors | NULL |
| Acquiror Sales | 40.75 billion U.S. Dollar
46.13 billion Swiss Franc |
|
 |
|
